Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
09 nov. 2022 07h05 HE
|
Clearside Biomedical, Inc.
- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability,...
Macular Degeneration Treatment Market, 2022: Industry surge ahead at a CAGR of 7.4% to reach US$ 18.8 Bn in 2032 - Persistence Market Research
03 nov. 2022 09h30 HE
|
Persistence Market Research
New York , Nov. 03, 2022 (GLOBE NEWSWIRE) -- The global macular degeneration treatment market recorded a CAGR of 6.2% in the last 9 years from 2012 to 2021 and reached a market value of around US$...
Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
29 avr. 2022 11h36 HE
|
Ocugen
MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and...
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
25 avr. 2022 07h33 HE
|
Ocugen
MALVERN, Pa., April 25, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and...
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
01 avr. 2022 07h37 HE
|
Ocugen
MALVERN, Pa., April 01, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and...
Ocugen, Inc. to Present at the 34th Annual ROTH Conference
09 mars 2022 07h11 HE
|
Ocugen
MALVERN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to...
Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases
10 août 2020 07h30 HE
|
Ocugen
MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease
27 juil. 2020 07h30 HE
|
Ocugen
MALVERN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
Foundation Fighting Blindness Celebrates 15th Year of VisionWalk with New Branding
09 janv. 2020 14h00 HE
|
Foundation Fighting Blindness
Columbia, MD, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The Foundation Fighting Blindness launches 2020 with a bold, new logo and branding for its signature fundraising event, VisionWalk. VisionWalk...